Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by longterm56on Sep 04, 2020 9:52pm
261 Views
Post# 31514802

RE:Is Next Week the Week?

RE:Is Next Week the Week?Have we lost all hope in a direct label expansion for Egrifta?  Can I dream that the length of negotiation (almost a year!!) along with Grinspoon's additional research results could yield an allowable use of Egrifta for some PLWH? 

Might as well dream big! 

    -LT


]With summer effectively over for most everyone, will the August deadzone of info from TH finally end? I suspect so. I don't know when news will satrt folowing from TH but there is potential for Spetember to be a busy month from a PR perspective. Here are some of the things that could be addressed soon:

1.) Most obviously, the HIV NASH phase III protocol
2.) An announcement about a new Egrifta patent that will give the company greater flexibility to pursue spending money on Egrifta trials, which could include future trials on other liver indications
3.) An announcement that Trogarzo sales have exceeded $55 million since inception and that TH will now get 48% of sales going forward versus the earlier 38%.
4.) Maybe a comment on what if anything they will do regarding the General NASH market
5.) Finalization of the IND for the phase I cancer trial. Maybe they will lay out some plans for how cancer trials will progress
6.) The intiation of sales in Germany and maybe Norway too (not that Norway likely matters much)

Maybe we will see new analysts pick up coverage of the stock as they hope to get a piece of any new share offering deal the company might do.

I imagine TH will spread out a bunch of press releases on issues liek those above over the month as they try to build momentum in the share price and get a decent price for any new shares they might sell. There has to be institutional interest in the stock based on their phase III HIV NASH program but the tiny market cap makes it difficult for institutions to get a decent amount of the stock without an offering. So, if they can get the share price up on the back of the positive news flow, I would expect them to sell some shares. 

They may not want to do a huge offering though as they might think they could sell more shares at a higher price next year after there is phase I cancer data. Or perhaps they could raise money via a partnership deal for either Egrifta in General NASH or for their new cancer platform. I also suspect the new CEO  might want to have some money in his back pocket in order to look to add to their pipeline of drugs.

In any event, we can't know what exactly might happen. But we can be pretty much assured there will be some good things happening very soon. 


[/quote]

Bullboard Posts